See the latest news and media coverage for Alpha Tau. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of alpha radiation therapy for cancer
alphatau.comLast updated
In short: Alpha Tau advanced its Alpha DaRT therapy through a strategic U.S. partnership, Japanese regulatory approval, and positive clinical trial results.
The procedure at Hadassah Medical Center in Jerusalem was completed safely. This marks the first international clinical application of the brain-specific delivery system.
The clearance follows an interim report showing 100% local disease control; two new U.S. sites were authorized.
Partnership brings AlphaDaRT therapy to U.S. urological cancer patients with $15M manufacturing investment and up to $161.5M milestones.
Pooled analysis of three Phase I/II studies shows encouraging median overall survival across patient populations with favorable safety profile.
The pilot study plans to enroll patients with locally recurrent prostate cancer across clinical trial sites in the US.
An announcement from Alpha Tau Medical Ltd ( (DRTS)) is now available. Alpha Tau Medical Ltd., a Jerusalem-based oncology company listed on Nasdaq, specializes in...
Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for...
Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for...
Track Alpha Tau and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.